Shares of Opko Health fell 9.5% in the extended trading session on Thursday after the company reported its third-quarter results.
Opko Health’s subsidiary BioReference Laboratories has launched a new multiplex test that will aid healthcare providers, clinics and health systems in the diagnosis …
BioReference Laboratories, a wholly-owned subsidiary of Opko Health, has commenced its COVID-19 testing program for New York City public schools. The testing will …
Opko Health announced the initiation of a Phase 2 trial of Rayaldee as a treatment for mild-to-moderate COVID-19. After rising in the pre-market …
Is Billionaire fund guru Jim Simons switching OPK for VRX?
How does Hedge fund guru Dmitry Balyasny’s choice to invest new stakes in Teva Pharmaceutical (NYSE:TEVA) and Synergy Pharmaceuticals (NASDAQ:SGYP) while bumping up …
Opko Health Inc. (NASDAQ:OPK) delivered a sore sight to the Street yesterday with a sharp third quarter miss in earnings that has sent …
Louise Chen: Even with less-than-impressive sales for the quarter, OPK stock still poses long-term value.
Opko Health Inc. (NASDAQ:OPK) reports operating and financial results for the three months ended September 30, 2017.
Opko Health Inc. (NASDAQ:OPK) reports financial and operating results for the three months ended December 31, 2016.
